Shares of Veru have moved -6.2% Friday, and are now trading at a price of $5.47. In contrast, the S&P 500 index saw a -0.7% change and the Dow Industrial Average posted a -0.6% performance. Today's trading volume is 3,073,258 compared to the stock's average volume of 4,939,223.
Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Based in Miami, United States the company has 233 full time employees and a market cap of $441,008,352. The company is now trading -65.27% away from its average analyst target price of $15.75 per share. The 4 analysts following the stock have set target prices ranging from $3 to $22, and on average give Veru a rating of buy.
Over the last year, VERU shares have gone down by -10.5%, which represents a difference of 5.3% when compared to the S&P 500. The stock's 52 week high is $24.55 per share and its 52 week low is $4.34. Based on Veru's average gross margin growth of 4.6% over the last four years, its core business remains strong and the stock price may recover in the long term.
